Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure

Yoav Michowitz, Emil Goldstein, Dov Wexler, David Sheps, Gad Keren, Jacob George*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Circulating endothelial progenitor cells (EPCs) are increased in conditions associated with ischaemia and can potentially support angiogenesis and vasculogenesis. EPC levels were also shown to predict outcome in patients with atherosclerotic vascular disease. We tested the hypothesis that circulating EPC can predict outcome in patients with congestive heart failure (CHF). Methods: EPC-colony-forming units were measured in the peripheral blood of 107 consecutive patients with CHF with New York Heart Association (NYHA) functional class II-IV. Serum levels of vascular endothelial growth factor (VEGF), N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) and high-sensitivity C-reactive protein (hsCRP) were also measured. End points were defined as CHF-related hospital admissions and all-cause mortality. Results: Age (p = 0.01), diabetes mellitus (p = 0.002) and EPC levels (p = 0.02) were found to be independent predictors of all-cause mortality. EPC levels did not predict CHF-related hospitalisations. EPC levels correlated positively with NYHA (p = 0.05, r = 0.19), but did not correlate with VEGF, NT-pro-BNP or hsCRP. EPC levels did not differ by the aetiology of CHF. Conclusions: EPC levels are independent predictors of all-cause mortality among patients with CHF.

Original languageEnglish
Pages (from-to)1046-1050
Number of pages5
Issue number9
StatePublished - Sep 2007


Dive into the research topics of 'Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure'. Together they form a unique fingerprint.

Cite this